German maker of prosthetic limbs, orthotic braces and wheelchairs that help people with disabilities and mobility limitations.
German maker of prosthetic limbs, orthotic braces and wheelchairs that help people with disabilities and mobility limitations.
Largely paid by health insurers, which reimburse the fitting of prosthetic limbs and braces, so rules and approval times matter. It makes the devices for sale to independent orthopedic workshops and also runs its own patient-care clinics, earning fitting and service fees there. The Naeder family, which has owned it for generations, keeps control.
In one line: A German Hanger Inc./Invacare for prosthetics and mobility devices.
Moat: narrow (brand, IP / patents, distribution). Leading global brand in advanced prosthetics with strong clinician relationships, but faces reimbursement-dependent demand.
Headquarters: Duderstadt, Germany · Founded: 1919 · Employees: 10,365
Size Ottobock SE & Co. KGaA (OBCK.DE) is a Germany Health Care company (Medical Specialties) with a market value of $2.65B, the 91st largest of 198 Germany companies the cockpit tracks. Shares closed at €37.75 on 18 Nov 2026.
Performance Over six months the shares fell 30.4%, against -2.2% for the median peer and -0.9% for the Germany market (cap-weighted) — 2nd lowest of 21 in its peer set.
Growth Revenue grew 4.7% over the last twelve months (peer median +3.1%); the operating margin is 16.7% (peer median 7.4%).
Valuation It trades at 12.3× forward earnings against a peer median of 24.4× (2nd cheapest of 19).
Price implies For today's price to make sense, revenue must grow about -1% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is -9 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 7.1 points above its cost of capital (6.4% WACC).
Next results Next results expected around 16 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | €1.77B | €1.68B | €1.60B | €1.50B | €1.33B |
| Revenue growth | — | +5% | +7% | +12% | — |
| Gross profit | €939M | €886M | €812M | €702M | €597M |
| EBITDA | €450M | €372M | €300M | €204M | €143M |
| Net income | €150M | €90.2M | €30.2M | €49.0M | €76.4M |
| Free cash flow | €159M | €176M | €112M | €57.7M | -€40.5M |
| Capital expenditure | €102M | €109M | €102M | €89.4M | €114M |
| Total debt | €1.18B | €1.05B | €1.20B | €1.19B | €1.19B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | OBCK.DE | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -26.1% | -3.0% | lowest of 21 |
| 6-month return | -30.4% | -2.2% | 2nd lowest of 21 |
| Distance from 52-week high | -50.6% | -28.4% | 4th lowest of 21 |
| Revenue growth (TTM) | +4.7% | +3.1% | 10th highest of 20 |
| Operating margin | 16.7% | 7.4% | 6th highest of 20 |
| Forward P/E | 12.3× | 24.4× | 2nd cheapest of 19 |
| Growth the price implies (Req g, 7 yrs) | -1.2% | 11.3% | 2nd least demanding of 15 |
| Growth delivered (Del g) | +8.0% | +8.5% | 8th highest of 15 |
| Hurdle (Req g minus delivered) | -9.2 pp | +6.1 pp | 3rd least demanding of 15 |
| ROIC minus cost of capital | +7.1 pp | -0.7 pp | 5th highest of 20 |
| EV / EBITDA | 7.8× | 17.1× | 2nd cheapest of 11 |
| Net debt / EBITDA | 2.4× | 1.5× | 4th most indebted of 12 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Ottobock SE & Co. KGaA OBCK.DE | Germany | $2.65B | -30% | +5% | 17% | 12.3× | -1.2% | +8.0% |
| Celcuity CELC | United States | $2.73B | -60% | n/a | n/a | n/a | n/a | n/a |
| COMET COTN.SW | Switzerland | $2.78B | -15% | -3% | 6% | 32.8× | n/a | n/a |
| EBOS EBO.AX | Australia | $2.50B | +7% | +3% | 3% | 15.7× | 4.7% | +6.8% |
| AtriCure ATRC | United States | $2.82B | +91% | +14% | 3% | 212.4× | 54.2% | +20.9% |
| Medacta MOVE.SW | Switzerland | $2.48B | -28% | +8% | 15% | 24.0× | n/a | n/a |
| Double Medical Technology 002901.SZ | China | $2.43B | -2% | +13% | 26% | 24.2× | 7.6% | +10.4% |
| Neogen NEOG | United States | $2.42B | +25% | 0% | 0% | 32.6× | n/a | n/a |
| Jafron Biomedical 300529.SZ | China | $2.35B | +3% | +1% | 37% | 24.3× | 6.1% | +0.6% |
| Elekta EKTA-B.ST | Sweden | $2.35B | 0% | -7% | 6% | 15.3× | 10.7% | +4.0% |
| Micro-Tech (Nanjing) 688029.SS | China | $2.33B | 0% | +6% | 18% | 28.1× | 11.9% | +19.2% |
| MGI Tech 688114.SS | China | $3.06B | -4% | +2% | -7% | n/a | 43.7% | -0.1% |
| Shanghai Conant Optical 2276.HK | Hong Kong | $2.25B | -17% | +8% | 29% | 22.1× | -1.1% | +14.1% |
| Carl Zeiss Meditec AFX.DE | Germany | $3.17B | +22% | 0% | 8% | 24.4× | 12.5% | +10.8% |
| iRhythm IRTC | United States | $3.19B | -19% | +22% | 5% | 99.8× | 46.9% | +23.0% |
| Lepu Medical Technology (Beijing) 300003.SZ | China | $3.20B | -13% | -1% | 13% | 24.4× | 8.7% | -4.2% |
| Metall Zug METN.SW | Switzerland | $2.19B | +20% | 0% | -10% | 139.8× | n/a | n/a |
| Zhende Medical 603301.SS | China | $3.26B | -10% | +8% | 7% | 42.5× | 22.9% | -16.1% |
| Draegerwerk AG & Co. KGaA DRW8.DE | Germany | $2.13B | +25% | +5% | 7% | 10.2× | -10.2% | +0.4% |
| iRay Technology 688301.SS | China | $3.31B | -30% | +58% | 24% | 25.7× | n/a | n/a |
| JEOL 6951.T | Japan | $2.12B | -2% | -15% | 12% | 15.5× | 22.2% | +10.2% |